Harrow (HROW) Cash from Investing Activities (2012 - 2026)
Harrow (HROW) posted quarterly Cash from Investing Activities of -$18.2 million for Q1 2026, down 8486.32% year-over-year from $217055.9 in Q1 2025, and down 284.84% quarter-over-quarter from -$4.7 million in Q4 2025.
Harrow (HROW) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Harrow's Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$18.2 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 8486.32% year-over-year to -$18.2 million; the TTM figure through Mar 2026 stood at -$23.5 million (up 29.5% YoY), while the FY2025 annual figure was -$5.5 million, up 83.54% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$18.2 million, down from -$4.7 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $5.1 million in Q2 2024, with the low at -$131.0 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$410000.0 (2022), against an average of -$12.4 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 31843.9% in 2023, then soared 508.57% in 2024.
- Harrow's Cash from Investing Activities stood at -$5000.0 in 2022, then plunged by 3960.0% to -$203000.0 in 2023, then tumbled by 18402.46% to -$37.6 million in 2024, then soared by 87.41% to -$4.7 million in 2025, then slumped by 284.84% to -$18.2 million in 2026.
- Business Quant data shows HROW's Cash from Investing Activities at -$18.2 million in Q1 2026, -$4.7 million in Q4 2025, and -$225000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Harrow | 1.53 Bn | 1.45 Bn | 50.36 Mn | -534,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -534,000.00 |
| Jun 30, 2026 | -534,000.00 |
| Mar 31, 2026 | -18.20 Mn |
| Mar 31, 2026 | -18.20 Mn |
| Dec 31, 2025 | -4.73 Mn |
| Dec 31, 2025 | -4.73 Mn |
| Sep 30, 2025 | -225,000.00 |
| Sep 30, 2025 | -225,000.00 |
| Jun 30, 2025 | -293,000.00 |
| Jun 30, 2025 | -293,000.00 |
| Mar 31, 2025 | -212,000.00 |
| Mar 31, 2025 | -212,000.00 |
| Dec 31, 2024 | -37.56 Mn |
| Dec 31, 2024 | -37.56 Mn |
| Sep 30, 2024 | -597,000.00 |
| Sep 30, 2024 | -597,000.00 |
| Jun 30, 2024 | 5.10 Mn |
| Jun 30, 2024 | 5.10 Mn |
| Mar 31, 2024 | -110,000.00 |
| Mar 31, 2024 | -110,000.00 |